Initially, GLP-1s were developed to treat type 2 diabetes and were marketed for that purpose under brand names such as Ozempic (semaglutide), Rybelsus (semaglutide), Victoza (liraglutide), and Mounjaro (tirzepatide)
Semaglutide also tends to produce more rapid and substantial weight loss than older GLP-1 medications, which aligns with the weight-loss-driven telogen effluvium hypothesis
MacDonald-Ramos, K., Michn, L., Martnez-Ibarra, A., & Cerbn, M
Shortland GJ, Walter JH, Stroud C, Fleming PJ, Speidel BD, Marlow N
This isnt a school science experiment